Media Coverage
Source: Bloomberg, Daily Journal, The Deal
Media Coverage
Press Contacts: Erik Cummins, Matt Hyams, Olivia Thomas
03.23.16
Pillsbury advised San Diego biotechnology company Celladon in its acquisition by Palo Alto’s Eiger BioPharmeceuticals Inc. in a deal reported on November 24, 2015. A group of investors including HBM Healthcare Investments AG, RA Capital Management LLC, Sabby Management LLC and Sphera Fund Management Ltd., have committed to invest $39.5 million in the combined company. The deal closed on March 23.
According to a news release, the deal creates a clinical-stage company with a diversified development portfolio of product candidates that address novel targets for four orphan diseases. The deal is subject to closing conditions, including stockholder approval.
San Diego partner Mike Hird led the team, which included partner Patty DeGaetano and associate Brandt Schmidt.